Abstract
New research on pharmaceutical-industry sponsorship of clinical research in breast cancer shows that treatment trials funded by the industry are more likely to show positive results than studies sponsored by other sources. There are also major differences in trial design when drug companies are the funders.
Get full access to this article
View all access options for this article.